Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents Awarded to Max Planck, Phigenix, and More

Premium

Title: RNA Sequence-specific Mediators of RNA Interference

Patent Number: 8,632,997

Filed: Oct. 4, 2010

Lead Inventor: Thomas Tuschl, Max Planck Institute


Title: dsRNA-induced Specific and Non-specific Immunity in Crustaceans and Other Invertebrates and Biodelivery Vehicles for use Therein

Patent Number: 8,633,028

Filed: July 2, 2004

Lead Inventor: Paul Gross, Medical University of South Carolina


Title: Targeting PAX2 for the Treatment of Breast Cancer

Patent Number: 8,633,149

Filed: May 24, 2011

Inventor: Donald Carlton, Phigenix


Title: siRNA Targeting Histamine Receptor H1

Patent Number: 8,633,306

Filed: Aug. 10, 2011

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.